摩根中国生物医药混合(QDII)C(019573)资产负债表
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 资产 |
| 银行存款 |
- |
- |
- |
| 结算备付金 |
2,459,379.84 |
923,861.96 |
589,022.78 |
| 存出保证金 |
2.03 |
43,910.15 |
- |
| 交易性金融资产 |
338,109,578.63 |
323,751,137.33 |
417,998,630.33 |
| 其中：股票投资 |
338,109,578.63 |
323,751,137.33 |
417,998,630.33 |
| 债券投资 |
- |
- |
- |
| 资产支持证券投资 |
- |
- |
- |
| 衍生金融资产 |
- |
- |
- |
| 买入返售金融资产 |
- |
- |
- |
| 应收证券清算款 |
158,964.98 |
11,278,571.66 |
- |
| 应收利息 |
- |
- |
- |
| 应收股利 |
- |
197,590.69 |
- |
| 应收申购款 |
212,441.46 |
285,766.53 |
399,528.23 |
| 其他资产 |
- |
- |
- |
| 资产总计 |
415,226,968.99 |
437,625,911.05 |
541,311,606.29 |
| 负 债 |
| 短期借款 |
- |
- |
- |
| 交易性金融负债 |
- |
- |
- |
| 衍生金融负债 |
- |
- |
- |
| 卖出回购金融资产款 |
- |
- |
- |
| 应付证券清算款 |
2,792,093.15 |
656,826.85 |
13,092.60 |
| 应付赎回款 |
1,517,415.23 |
2,328,475.85 |
2,506,098.43 |
| 应付管理人报酬 |
538,788.91 |
556,866.20 |
693,750.82 |
| 应付托管费 |
89,798.15 |
92,811.01 |
115,625.11 |
| 应付销售服务费 |
576.41 |
415.01 |
185.10 |
| 应付交易费用 |
- |
- |
- |
| 应交税费 |
- |
- |
- |
| 应付利息 |
- |
- |
- |
| 应付利润 |
- |
- |
- |
| 其他负债 |
344,159.94 |
950,419.36 |
573,800.21 |
| 负债合计 |
5,282,831.79 |
4,585,814.28 |
3,902,552.27 |
| 所有者权益 |
| 实收基金 |
430,703,278.78 |
451,521,650.02 |
473,324,191.76 |
| 未分配利润 |
-20,759,141.58 |
-18,481,553.25 |
64,084,862.26 |
| 所有者权益合计 |
409,944,137.20 |
433,040,096.77 |
537,409,054.02 |
| 负债及所有者权益总计 |
415,226,968.99 |
437,625,911.05 |
541,311,606.29 |
微信公众号
证券之星APP
基本资料
